Bio-Rad Labs (BIO) Q4 Revs Beat Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts BIO Hot Sheet
Price: $369.95 +1.77%
EPS Growth %: -1.3%
Financial Fact:
Selling, general and administrative expense: 205.54M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -1.3%
Financial Fact:
Selling, general and administrative expense: 205.54M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $2.32, which includes tax gains and does not compare to the analyst estimate of $1.26. Revenue for the quarter came in at $620.4 million versus the consensus estimate of $619.15 million.
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
- AI-powered cyber threats light a fire under cybersecurity stocks
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
